Today: 9 June 2026
IREN stock ends 2025 lower as bitcoin slips — what traders watch next
1 January 2026
1 min read

IREN stock ends 2025 lower as bitcoin slips — what traders watch next

NEW YORK, December 31, 2025, 18:13 ET — After-hours

  • IREN closed down about 1.4% at $37.77; shares were little changed after the bell
  • Bitcoin eased below $88,000 as risk appetite stayed fragile into year-end
  • Crypto miners mostly fell, with Marathon and CleanSpark under pressure

IREN Limited (IREN) shares fell 1.4% to $37.77 at Wednesday’s close, extending a three-session slide to end the year. The stock edged up 0.1% to $37.81 in after-hours trading after moving between $37.20 and $39.03 in the session, with about 20.7 million shares changing hands.

The move comes as crypto-linked equities stay tethered to shifting risk appetite late in the year, with bitcoin on track for its first annual loss since 2022. “Bitcoin increasingly exhibits the characteristics of a risk asset,” said Linh Tran, a senior market analyst at XS.com. Reuters

Bitcoin was down about 0.9% near $87,600 in late New York trading, and miners were mixed-to-lower. Marathon Digital was down about 3.6%, CleanSpark slipped about 2.9% and Riot Platforms eased about 0.4%.

IREN, which operates renewable-powered data centers, has drawn attention for pushing beyond bitcoin mining into AI cloud services. Microsoft struck a five-year $9.7 billion agreement with IREN in November that includes access to Nvidia’s GB300 processors, and IREN said the chips are scheduled for phased deployment through 2026 at its Childress, Texas campus. IREN also said the Microsoft contract can be terminated if it fails to meet delivery timelines.

GPU cloud, in plain terms, is rented access to specialized graphics processors used to train and run AI models. That puts IREN in the cross-currents of both crypto sentiment and the AI infrastructure trade, where power, cooling and chip supply can quickly become the binding constraints.

To help finance expansion, IREN raised capital earlier this month through convertible notes and an ordinary share offering aimed at repurchasing existing convertible notes, the company said. Convertible notes are bonds that can convert into stock, which can increase the share count over time.

For traders, the near-term question is whether the stock can stabilize after slipping under the $40 round-number level that often acts as a technical reference point. Wednesday’s low near $37.20 is the next obvious support level on the chart.

Macro and crypto price action remain the immediate swing factors. A further drop in bitcoin would typically pressure miners through weaker mining economics, while a rebound in risk appetite can lift the group quickly given its high volatility.

The next scheduled checkpoint is earnings, where investors will look for updates on AI cloud revenue, capital spending and progress on deployments tied to customer contracts. StockAnalysis lists an estimated Feb. 11, 2026 earnings date.

Until then, IREN is likely to trade as a barometer of two narratives at once: bitcoin’s direction and confidence that AI-related data center buildouts can scale without outsized dilution or delivery setbacks.

Stock Market Today

  • Evotec Shares Slide Amid Losses and Valuation Debate
    June 8, 2026, 10:00 PM EDT. Evotec (XTRA:EVT) shares dropped about 31% over the past year despite modest revenue growth and notable pharma partnerships. Trading near €4.93, the stock is about 28% undervalued versus a fair value estimate of €6.83 but remains unprofitable. Investors face a critical choice amid ongoing losses and reliance on future execution to boost margins and revenues. The biotech's shift to technology licensing and expanding pharma deals may enhance cash flow, yet risks include dependency on key clients and limited internal production capacity. Analysts caution that valuation hinges on the arrival of sustained profits. Prospective investors should evaluate these factors amid mixed market sentiment.

Latest articles

Chip Rally Breaks as Nasdaq Faces Tight Labor Market

Nasdaq rises after hours as chips recover

9 June 2026
Nasdaq jumped 0.86% as chip stocks rebounded, with Intel soaring 11.2% on news Google ordered over 3 million AI chips for 2028, while Apple slid 1.9% after unveiling new AI features. Investors await Wednesday’s May CPI inflation report, which could spark volatility in tech and growth stocks.
Broadcom Stock Rebounds, AI Remains an Open Question for Wall Street

Broadcom Stock Rebounds, AI Remains an Open Question for Wall Street

9 June 2026
Broadcom shares jumped 2.8% to $396.60 as chip stocks rebounded after last week’s $1 trillion sector wipeout, but investors remain cautious after Broadcom’s Q2 revenue missed expectations and the company declined to raise its 2027 AI revenue forecast, fueling concerns that rapid AI growth may not meet Wall Street’s high demands.
BitMine Stock Gains as Ether Holdings Approach 5% Target

BitMine Stock Gains as Ether Holdings Approach 5% Target

9 June 2026
BitMine Immersion Technologies shares jumped 6% after revealing ether holdings climbed to 5.54 million tokens, now 4.59% of Ethereum’s supply, with $9.6 billion in crypto, cash and stakes. The company priced a $273.8 million preferred stock offering, with proceeds possibly funding more ETH purchases and staking. BitMine projects $230 million in annualized staking revenues but warns of risks if ETH or financing falters.
Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

9 June 2026
Mingteng International shares soared 81.3% to $1.94 after the company ended its at-the-market stock sale plan, having raised about $20.6 million in gross proceeds; trading volume hit 24.2 million, dwarfing its $12 million market value, as the move outpaced gains in other U.S.-listed China auto stocks.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop